Leap‐Type Response of Redox/Photo‐Active Lanthanide‐Based Metal–Organic Frameworks for Early and Accurate Screening of Prostate Cancer
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202411956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Kaiming Ge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Low Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials…. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Prostatic Neoplasms, Oxidation-Reduction, Lanthanoid Series Elements. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Basic Research Program of Shanghai.
Abstract (Originalsprache)
The development of high‐accuracy technologies to distinguish the quite tiny concentration change of tumor markers between negative and positive is of vital significance for early screening and diagnosis of cancers, but is still a great challenge for the conventional biosensors because of their “gradual” detection mode. Herein, a unique “leap‐type” responsive lanthanide MOF‐based biosensor (designated as Tb‐CeMOF‐X) with defect‐mediated redox‐/photo‐activities is developed for precisely identifying acid phosphatase (ACP), an early pathological marker of prostate cancer (PCa) in serum. The engineered Tb‐CeMOF‐X probe achieves a bursting switch‐on luminescence at the critical concentration of ACP (9 U ⋅ L −1 ), while keeping silent below this threshold, undergoing a qualitative signal change from “zero” to “one” between negative and positive indicators and thus significantly improving the identification precision. Significantly, such “leap‐type” response performance can be further edited and amplified by rational defect engineering in the crystal structure to improve the accessibility of active centers, consequently maximizing the detection sensitivity toward ACP in the complex biological media. This study proposes the first paradigm for the development of “leap‐type” biosensors with ultra‐sensitive differentiation capability between negative and positive, and provides a potentially valuable tool for early and accurate screening of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Low Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, Shanghai Engineering Research Center o…
- School of Chemistry and Chemical Engineering, State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, Shihezi University, Shihezi, 832003, China.
ORCID-Profile: Yongsheng Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Basic Research Program of Shanghai
- Shanghai Rising-Star Program
- Natural Science Foundation of Shanghai Municipality
- Leading Talents in Shanghai in 2018
- Higher Education Discipline Innovation Project
Zitieren
APA
Ge, K., Chen, G., Zhang, D., Hao, J. N., & Li, Y. (2024). Leap‐Type Response of Redox/Photo‐Active Lanthanide‐Based Metal–Organic Frameworks for Early and Accurate Screening of Prostate Cancer. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202411956
Vancouver
Ge K, Chen G, Zhang D, Hao JN, Li Y. Leap‐Type Response of Redox/Photo‐Active Lanthanide‐Based Metal–Organic Frameworks for Early and Accurate Screening of Prostate Cancer. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202411956
BibTeX
@article{Ge2024,
author = {Ge, Kaiming and Chen, Guoli and Zhang, Dapeng and Hao, Ji-Na and Li, Yongsheng},
title = {Leap‐Type Response of Redox/Photo‐Active Lanthanide‐Based Metal–Organic Frameworks for Early and Accurate Screening of Prostate Cancer},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202411956}
}
EUVIMED